Key Takeaways
- Shares of Moderna surged up to 9.1% following positive FDA briefing documents that revealed no significant deficiencies in the mFlusiva mRNA flu vaccine application
- The Vaccines and Related Biological Products Advisory Committee (VRBPAC) will convene June 18 to assess whether mFlusiva’s benefits justify its risks for individuals 50 years and older
- Approval would mark mFlusiva as the first mRNA-based seasonal influenza vaccine authorized in the United States, with a final FDA ruling anticipated by August 5
- The biotech firm is pursuing standard approval for the 50â64 age bracket and accelerated approval for those 65 and above
- Concurrent with the regulatory progress, Moderna revealed organizational changes, appointing Ester Banque to Chief Commercial Officer as it prepares for multiple product rollouts between 2027 and 2028
Shares of Moderna (MRNA) rallied as much as 9.1% on Tuesday following the release of FDA staff briefing documents indicating that data supporting its mFlusiva flu vaccine may demonstrate effectiveness in adults aged 65 and older. The stock traded near $56.12, approaching its 52-week peak of $57.80.
The briefing materials surfaced prior to Thursday’s scheduled Vaccines and Related Biological Products Advisory Committee (VRBPAC) meeting, where panel members will determine whether mFlusiva’s benefits justify its risks for the 50-and-older population.
Notably, FDA staff identified no “major deficiencies” in the submissionâthe positive signal market participants had been anticipating.
The regulatory journey hasn’t been smooth. This past February, the agency issued a refuse-to-file letter over concerns about trial methodology, particularly that the control group for seniors 65 and up received standard-dose flu vaccines instead of the high-dose formulation recommended by the CDC for that demographic. The FDA reversed its position shortly after Moderna proposed modifications to its filing.
That regulatory whiplash created uncertainty among investors. Tuesday’s documentation represented a notable shift in regulatory sentiment.
Jefferies analyst Andrew Tsai characterized the evaluation as encouraging, forecasting combined U.S. revenue of $750 million from flu and COVID-flu combination vaccines by 2030.
FDA Staff Assessment Details
According to FDA reviewers, mFlusiva demonstrated superior relative vaccine efficacy compared to standard-dose flu vaccines in the 50 to 64 age cohort. For individuals 65 and older, the submission relies primarily on immunogenicity measurements rather than direct efficacy comparisons against high-dose alternatives.
Reviewers acknowledged certain constraints. The vaccine has undergone testing during only a single influenza season, and trial populations excluded immunocompromised individuals and significantly frail elderly participants, creating uncertainty about real-world performance in those populations.
Moderna has committed to conducting supplementary research and providing additional data for the 65-plus demographic should it secure accelerated approval for that segment.
The pharmaceutical company seeks conventional approval for adults aged 50 to 64 and accelerated approval for the 65-and-older group. A conclusive FDA determination is anticipated by August 5.
If greenlit, mFlusiva would represent the inaugural mRNA-based seasonal influenza vaccine authorized in the U.S. market.
Leadership Reorganization Positions Moderna for Product Expansion
Coinciding with the regulatory developments, Moderna unveiled structural changes to its executive team. The company named Ester Banque as Chief Commercial Officer, a strategic appointment designed to position the organization for as many as three product introductionsâincluding a flu/COVID combination vaccine and a norovirus vaccineâplanned for the 2027-2028 timeframe.
The convergence of improved regulatory prospects and defined commercial strategy provided sufficient momentum to drive the stock price upward.
Moderna has gained 81.8% year-to-date. However, despite this impressive run, investors who allocated $1,000 to MRNA five years ago would currently hold just $283.65.
The VRBPAC advisory vote is set for June 18.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
